Your browser doesn't support javascript.
loading
Trophoblast Cell Surface Antigen 2 (Trop2) in Chromophobe Renal Cell Carcinoma.
Mikuteit, Marie; Steffens, Sandra; Zschäbitz, Stefanie; Autenrieth, Michael; Weichert, Wilko; Hartmann, Arndt; Erlmeier, Franziska.
Afiliación
  • Mikuteit M; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Steffens S; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Zschäbitz S; Department of Urology, University Hospital Münster, Münster, Germany.
  • Autenrieth M; Department of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Weichert W; Department of Urology, Technical University of Munich, Klinikum Rechts der Isar, Munich, Germany.
  • Hartmann A; Institute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
  • Erlmeier F; Member of the German Cancer Consortium (DKTK), Munich, Germany.
Oncology ; 100(6): 331-336, 2022.
Article en En | MEDLINE | ID: mdl-35168242
BACKGROUND: Overexpression of tumor-associated calcium signal transducer 2 (Trop2) is found in many tumor entities. The prognostic value of Trop2 in renal cell renal carcinoma (RCC), especially in nonclear cell RCC, is still unclear. AIM: The aim of this study was to evaluate the prognostic impact of Trop2 expression in a large cohort of patients with chromophobe (ch)RCC. MATERIALS AND METHODS: Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for Trop2 expression by immunohistochemistry. RESULTS: Eighty-one chRCC patients were eligible for analysis, of these 24 (29.6%) patients were positive for Trop2. No significant associations were found for Trop2 expression and clinical attributes in patients with chRCC. The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Trop2- compared to Trop2+ (89.6% vs. 100.0%; p = 0.288). CONCLUSION: In chRCC, Trop2 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further studies with larger cohorts are warranted.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Oncology Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Oncology Año: 2022 Tipo del documento: Article País de afiliación: Alemania